Enzymotec Granted Mexican Patent for INFAT® Uses Related to Promoting Intestinal Health

MIGDAL HA'EMEQ, Israel, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that INFAT®, the innovative ingredient that is marketed by Advanced Lipids, an AAK and Enzymotec joint venture, was granted a patent by the Mexican Patent Office for uses related to promoting intestinal health.

INFAT®, developed specifically for infant formula, is a clinically-proven fat ingredient that closely resembles the composition, structure and nutritional value of the natural fat found in human breast milk, which is necessary for proper infant health, development and comfort. The patent relates to a vegetable-derived, enzymatically prepared lipid composition, comprising of triglycerides with 15-55% palmitic acid of which at least 30% are in the middle position, for promoting the development of beneficial gut flora.

“We are pleased to add another patent to our robust worldwide intellectual property portfolio, which serves as the cornerstone of our strategy to lead the market through innovation. We provide our INFAT® customers with a clear competitive edge, which puts them at the forefront of a crowded space," commented Mr. Avner Avissara, CEO of Advanced Lipids and Enzymotec’s VP of Sales for Infant Nutrition, Nutrition Division. "We remain focused on our research and development and continue to innovate to further develop the benefits of INFAT® and create value for our customers."

Previously published clinical data demonstrated that infants fed with formula containing INFAT® developed a similar variety of beneficial gut bacteria as breastfed babies. Beneficial gut bacteria promote good health and development, and the ability to prevent infections.

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures, and markets innovative bio-active lipid based nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies intended to improve people’s health. For more information, visit www.enzymotec.com.

About Advanced Lipids

Advanced Lipids is a joint venture of AAK and Enzymotec. For more information, visit www.advancedlipids.com.

Forward Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the following risks: A high proportion of the sales of the InFat product is sold to end users in China and to a single company; Growth in the Chinese economy has moderated and this slowdown and related volatility could adversely impact demand in China for our products; The demand for products based on Omega-3 and in particular, premium products, such as krill oil, has declined and may continue to decline following a significant increase in manufacturing capacity by manufacturers of these products, resulting in intense competition and price pressure; Our offering of products as "medical foods" in the United States may be challenged by regulatory authorities; We rely on our Swedish joint venture partner to manufacture InFat and certain matters related to the joint venture are the subject of disagreement in an arbitration proceeding; We are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; We depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; We are dependent on a single facility that houses the majority of our operations; We may have to pay royalties with respect to sales of our krill oil products in the United States or Australia and any infringement of intellectual property of others could also require us to pay royalties; Potential future acquisitions of companies or technologies may distract our management, may disrupt our business and may not yield the returns expected; We anticipate that the markets in which we participate will become more competitive and we may be unable to compete effectively; We may not be able to successfully expand our production or processing capabilities; Our ability to obtain krill may be affected by conservation regulation or initiatives; Our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on March 2, 2015. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 tbui@theruthgroup.com lroth@theruthgroup.com

Source:Enzymotec Ltd.